223 related articles for article (PubMed ID: 33168045)
1. Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Chen NB; Li QW; Zhu ZF; Wang YM; Cheng ZJ; Hui ZG; Guo SP; He HQ; Wang B; Huang XY; Li JB; Guo JY; Hu N; Ai XL; Zhou Y; Wang DQ; Liu FJ; Xie CM; Qiu B; Liu H
Radiat Oncol; 2020 Nov; 15(1):260. PubMed ID: 33168045
[TBL] [Abstract][Full Text] [Related]
2. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
3. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
Pu Y; Zhang JX; Liu H; Appelbaum D; Meng J; Penney BC
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2079-2092. PubMed ID: 29882161
[TBL] [Abstract][Full Text] [Related]
4. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.
Choi HS; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH; Kang KM
Radiat Oncol; 2017 Jul; 12(1):122. PubMed ID: 28732516
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
Ostheimer C; Mäurer M; Ebert N; Schmitt D; Krug D; Baumann R; Henkenberens C; Giordano FA; Sautter L; López G; Fleischmann DF; Niyazi M; Käsmann L; Kaul D; Thieme AH; Billiet C; Dobiasch S; Arnold CR; Oertel M; Haussmann J; Gauer T; Goy Y; Suess C; Ziegler S; Panje CM; Baues C; Trommer M; Skripcak T; Medenwald D
Strahlenther Onkol; 2021 May; 197(5):385-395. PubMed ID: 33410959
[TBL] [Abstract][Full Text] [Related]
6. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
De Petris L; Lax I; Sirzén F; Friesland S
Med Oncol; 2005; 22(4):375-81. PubMed ID: 16260855
[TBL] [Abstract][Full Text] [Related]
7. Modern induction chemotherapy before chemoradiation for bulky locally-advanced nonsmall cell lung cancer improves survival.
Ahmed I; Ferro A; Baby R; Malhotra J; Cohler A; Langenfeld J; Aisner J; Zou W; Jabbour SK
J Cancer Res Ther; 2016; 12(2):952-8. PubMed ID: 27461680
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):612-20. PubMed ID: 26867890
[TBL] [Abstract][Full Text] [Related]
9. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
[TBL] [Abstract][Full Text] [Related]
10. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
[TBL] [Abstract][Full Text] [Related]
11. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
[TBL] [Abstract][Full Text] [Related]
12. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
13. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
[No Abstract] [Full Text] [Related]
14. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
[No Abstract] [Full Text] [Related]
15. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
[TBL] [Abstract][Full Text] [Related]
16. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
Reymen B; Van Loon J; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1319-24. PubMed ID: 23200174
[TBL] [Abstract][Full Text] [Related]
17. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
Finkle JH; Penney BC; Pu Y
Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
[TBL] [Abstract][Full Text] [Related]
18. CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment.
Chen NB; Xiong M; Zhou R; Zhou Y; Qiu B; Luo YF; Zhou S; Chu C; Li QW; Wang B; Jiang HH; Guo JY; Peng KQ; Xie CM; Liu H
Radiat Oncol; 2022 Nov; 17(1):184. PubMed ID: 36384755
[TBL] [Abstract][Full Text] [Related]
19. Excessive splenic volume is an unfavorable prognostic factor in patients with non-small cell lung cancer treated with chemoradiotherapy.
Guo J; Wang L; Wang X; Li L; Lü Y; Wang C; Hao C; Zhang J
Medicine (Baltimore); 2020 Dec; 99(49):e23321. PubMed ID: 33285708
[TBL] [Abstract][Full Text] [Related]
20. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
